Research programme: Bruton's tyrosine kinase inhibitors - Redx Pharma/Loxo Oncology

Drug Profile

Research programme: Bruton's tyrosine kinase inhibitors - Redx Pharma/Loxo Oncology

Alternative Names: LOXO 305; RXC 005

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Redx Pharma
  • Developer Loxo Oncology; Redx Pharma
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma

Most Recent Events

  • 08 May 2018 Loxo Oncology plans a phase I trial of LOXO 305 for B-cell lymphoma in USA in the second half of 2018
  • 20 Apr 2018 Loxo Oncology has patents pending for BTK inhibitors program in USA
  • 31 Jul 2017 Preclinical trials in B-cell lymphoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top